0546 GMT - Sandoz's sales miss is disappointing but prospects should improve in the second half due to a wave of upcoming biosimilar launches, RBC Capital Markets analysts say in a note. The Swiss generics maker stuck to its 2025 outlook, and confirmed it can absorb its current tariff exposure, despite 1Q sales that missed expectations on weaker demand in North America, they say. Sandoz has called out a lower private label pricing for its autoimmune disease treatment adalimumab, which will likely be the focus of analysts and investors, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 01:46 ET (05:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。